IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

Challenges of Counterfeit Drugs in the Indian Market: A Comprehensive Review

Vishal Shankar Jadhav and Archana T. Chaskar
Sahakar Maharshi Kisanrao Varal Patil College of Pharmacy, Nighoj

Abstract: *The proliferation of counterfeit, substandard, and falsified medicines represents a critical public health crisis in India, undermining decades of therapeutic advancement and threatening patient safety across all therapeutic categories. This review examines the epidemiology, regulatory landscape, supply chain vulnerabilities, health consequences, and proposed interventions for combating counterfeit pharmaceuticals in the Indian market. A comprehensive analysis of recent literature reveals that India ranks as the world's fourth largest market for counterfeit and substandard medicines, with prevalence estimates suggesting that one in five medicines sold in major Indian cities may be counterfeit. The global counterfeit drug market is valued at approximately $200 billion USD annually, with 67% of these medicines classified as dangerous to human health. Beyond direct patient harm, counterfeit antimicrobials—particularly antibiotics and antimalarials—are neglected drivers of antimicrobial resistance, contributing to an estimated 58,000 antibiotic-related deaths annually in India alone. This paper synthesizes current evidence on definitional frameworks, prevalence patterns, vulnerable drug categories, distribution channels, regulatory mechanisms, detection methodologies, and evidence-based interventions. The analysis identifies critical workforce shortages, supply chain opacity at the active pharmaceutical ingredient level, inadequate regulatory enforcement, and gaps in pharmacovigilance infrastructure as primary systemic barriers. Recommendations include strengthening the regulatory apparatus through technological innovation (serialization, blockchain-based tracking, portable analytical devices), expanding the pharmacovigilance network beyond current capacity, implementing workforce planning reforms, enhancing inter-state coordination, and establishing international cooperation mechanisms. The urgency of addressing this challenge is underscored by documented health consequences including acute renal failure, severe hypoglycaemia, toxic encephalopathy, and treatment failures in communicable disease programs, affecting both pediatric and adult populations*

Keywords: counterfeit medicines, pharmaceutical fraud, drug safety, India, antimicrobial resistance, regulatory framework, pharmacovigilance, public health

I. INTRODUCTION

The circulation of counterfeit, substandard, and falsified medicines (SSFFC) has emerged as one of the most insidious threats to global health security, yet it remains systematically understudied and underfunded in most low- and middle-income countries (LMICs). India, paradoxically positioned as the world's largest producer of generic medicines and a leader in pharmaceutical innovation, simultaneously represents a major hub for counterfeit drug manufacturing and a lucrative market for their distribution[1].

The problem spans far beyond simple cases of misidentification or cosmetic fraud. Counterfeit pharmaceuticals represent deliberate and fraudulent mislabeling with respect to identity, authenticity, effectiveness, composition, and source of finished medicinal products or their ingredients. The consequences manifest across multiple dimensions: patients receive subtherapeutic doses or entirely inert substances; resistant pathogenic strains emerge as organisms are exposed to subeffective antibiotic concentrations; toxic adulterants cause acute organ failure; and public confidence in the healthcare system erodes, driving patients toward increasingly unregulated informal sectors[2].

The Indian pharmaceutical market presents a particularly complex scenario. With approximately 89.8 million adults living with diabetes, tuberculosis incidence rates among the highest globally, and malaria remaining endemic in

DOI: 10.48175/IJARSCT-31001

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

multiple states, India's population depends critically on access to authentic, effective medications. Yet the same characteristics that have made India an attractive destination for legitimate pharmaceutical manufacturing—cost-competitive production, large unregulated retail networks, porous inter-state boundaries, and relatively weak enforcement capacity—have simultaneously created ideal conditions for counterfeit drug proliferation[3].

This review synthesizes current evidence on the epidemiology, mechanisms, health consequences, and regulatory responses to counterfeit drug challenges in India, with the objective of identifying evidence-based interventions for policymakers, regulatory authorities, healthcare professionals, and researchers[4].

Definitions and Classification Framework

Clarity in terminology is essential, as definitional inconsistencies across jurisdictions have historically obscured the true scale of the problem. The World Health Organization (WHO) defines counterfeit medicines as products that are deliberately and fraudulently mislabeled regarding identity, authenticity, effectiveness, composition, and/or source. This overarching category encompasses several subcategories[5]:

- **Counterfeit (Falsified) Medicines:** Products bearing fraudulent trademarks, packaging, and labeling, often manufactured entirely outside legitimate supply chains. These may contain incorrect active pharmaceutical ingredients (APIs), no active ingredient at all, or toxic adulterants[6].
- **Substandard Medicines:** Legitimately manufactured products that fail to meet pharmacopeial standards or specifications. These may result from manufacturing defects, improper storage conditions, or aging-related degradation, and may pass through licensed distribution channels[7].
- **Spurious Medicines:** Products fraudulently represented as originating from legitimate manufacturers when they do not. This category frequently involves relabeling of expired medicines, repackaging of lower-grade products, or misattribution of manufacturing facilities[8].
- **Unregistered/Unlicensed Medicines:** Products lacking regulatory approval or authorization in the jurisdiction where they are sold, even if manufactured under ostensibly legitimate conditions elsewhere.

The distinction between substandard and counterfeit medicines carries regulatory and public health implications, as substandard products may require remediation within existing supply chains, while counterfeit products necessitate market removal and criminal investigation. However, from a patient safety perspective, both categories present comparable risks of therapeutic failure, adverse outcomes, and antimicrobial resistance emergence[9].

II. EPIDEMIOLOGY AND PREVALENCE IN INDIA

Global Context and India's Position

According to WHO estimates, counterfeit medicines represent approximately 10% of the global drug trade, though this estimate varies substantially by geography, therapeutic category, and data collection methodology. The global counterfeit pharmaceutical market is valued at $200 billion USD annually, with 67% of these products categorized as dangerous to human health based on toxicological assessments. Developing countries bear disproportionate burden, with LMICs accounting for approximately 56% of documented counterfeit incidents involving serious adverse outcomes[10].

India occupies a unique and problematic position within this global landscape. India is simultaneously:

The world's largest producer of generic medicines, accounting for approximately 80% of WHO-prequalified generic drugs globally, with substantial investment in quality control systems compliant with Good Manufacturing Practice (GMP) standards. The fourth largest export-import market for counterfeit and substandard medicines, ahead of most developing nations but behind China, Nigeria, and several Southeast Asian countries

A major source of counterfeit drugs distributed globally, with evidence of Indian-manufactured counterfeits appearing in pharmaceutical supplies throughout Africa, Asia, and Latin America[11].

Prevalence Estimates in India

Estimating the precise prevalence of counterfeit drugs in the Indian market is methodologically challenging due to:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

- Absence of centralized surveillance data collection systems
- Geographic variation in enforcement capacity and market structure
- Heterogeneity in sampling methodologies across published studies
- Limited resources for systematic market surveillance

Despite these limitations, available evidence suggests concerning prevalence rates. Industry estimates suggest that one in every five strips of medicines sold in India's major cities may be counterfeit, generating an estimated 4-5% annual revenue loss for legitimate pharmaceutical manufacturers. Some studies, employing chemical analysis of pharmaceuticals purchased from retail outlets across multiple Indian states, report prevalence rates ranging from 10% to over 30% for specific therapeutic categories, particularly antibiotics and antimalarials.

A systematic review of substandard and counterfeit medicine prevalence across multiple studies found a global median prevalence of 28.5% (range: 0-100%), with disproportionately high rates in sub-Saharan Africa and South Asia. While comparable Indian-specific systematic reviews are limited, fragmented data from state-level enforcement agencies and industry sources suggest that India's prevalence patterns mirror or exceed these global estimates for certain drug categories and geographic regions[12].

III. VULNERABLE DRUG CATEGORIES AND THERAPEUTIC TARGETS

Antimicrobial Dominance

The most frequently counterfeited pharmaceutical categories globally and within India are antimicrobials, particularly:

- **Antibiotics:** Beta-lactam antibiotics (penicillins, cephalosporins) represent the most commonly counterfeited antibiotic class, followed by fluoroquinolones and macrolides. The high prevalence reflects multiple factors: widespread use across human and veterinary medicine, significant price differentials between branded and generic formulations, critical importance in treating life-threatening infections, and relatively simple chemical synthesis enabling unauthorized manufacturers to produce structurally similar compounds[13].
- **Antimalarials:** Chloroquine and artemisinin derivatives are extensively counterfeited, particularly in malaria-endemic regions of India. Counterfeit artemisinin-based combination therapies (ACTs) represent a specific concern given their role as first-line treatments for Plasmodium falciparum malaria.
- **Anti-tuberculosis Medicines:** Fixed-dose combinations (FDCs) of first-line anti-TB drugs are increasingly targeted, with consequences extending beyond individual patient outcomes to population-level emergence of drug-resistant tuberculosis[14].

Geographic and Therapeutic Patterns

Beyond antimicrobials, several other therapeutic categories are vulnerable:

- **Anticonvulsants:** Phenytoin and other anticonvulsants are frequently counterfeited, with seizure recurrence and status epilepticus documented as consequences of counterfeit substitution.
- **Cardiovascular Medications:** Antihypertensives and cardiac glycosides are periodically targeted, though with lower frequency than antimicrobials.
- **Reproductive Health Medicines:** Oral contraceptives and hormonal medications appear with notable frequency in counterfeit markets, though with less documentation of clinical consequences.

The predominance of antimicrobials in counterfeit markets reflects rational targeting by counterfeiters: these drugs command significant market volumes, cost differentials between branded and generic versions justify fraud, and detection requires specialized chemical analysis unavailable in most retail pharmacy settings[15].

Mechanisms of Counterfeit Drug Distribution

Supply Chain Vulnerabilities

The Indian pharmaceutical supply chain presents multiple structural vulnerabilities that enable counterfeit infiltration:

- **Active Pharmaceutical Ingredient Production:** India procures approximately 70% of its active pharmaceutical ingredients (APIs) from China. This concentration creates a critical vulnerability at the

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

upstream end of the supply chain. The vast majority of research on medicine supply chains has focused on formulation and distribution of finished products, overlooking crucial API procurement and manufacturing steps where counterfeit or substandard ingredients can be introduced. Regulatory oversight of API manufacturers is often weaker than oversight of finished product manufacturers, and supply chain transparency at this level remains limited[16].

- **Multi-tiered Distribution Networks:** The Indian pharmaceutical distribution system comprises multiple layers—manufacturers, wholesalers, sub-wholesalers, stockists, and retail pharmacies—with limited integration or information systems. This fragmentation creates numerous opportunities for counterfeit products to be introduced at various points. An assessment of pharmaceutical supply chains in Pakistan (with comparable structural features to India) found that informal retail outlets showed counterfeit failure rates of 35%, significantly exceeding licensed pharmacy rates[17].
- **Online Pharmacy Expansion:** E-commerce platforms for pharmaceutical sales have expanded substantially in India, creating a distribution channel with reduced oversight capacity. Studies examining online pharmacies have documented that while many legitimate online providers request prescriptions, some do not, and verification mechanisms for product authenticity are limited.

Retail and Consumer-Facing Distribution

At the consumer-facing end of the supply chain, multiple distribution mechanisms enable counterfeit drugs to reach patients:

- **Unlicensed Retail Outlets:** Informal pharmacies operating without proper licensing represent a major distribution point, particularly in rural areas and low-income urban neighborhoods. Unlike licensed pharmacies, which operate under regulatory scrutiny, unlicensed retailers face minimal enforcement pressure.
- **Community Pharmacy Practices:** Even licensed pharmacies may dispense counterfeit products due to pressure from wholesalers, inadequate training in authentication, limited consumer demand for authentication verification, or direct complicity in fraud[18].
- **Relabeling and Recirculation of Expired Medicines:** A documented case study from Chennai, India describes an extensive "Spurious Drugs Kingpin" operation that systematically relabeled and recirculated expired medicines, altering batch numbers, manufacturing dates, and packaging to create the appearance of legitimate products. This mechanism allows counterfeiters to operate with lower manufacturing costs while exploiting existing packaging infrastructure.
- **Wholesale Distribution Incentive Structures:** Qualitative research with pharmaceutical wholesalers in India's National Capital Region identified that wholesaler compensation structures—including volume discounts and incentive schemes—often inadvertently encourage or tacitly enable the distribution of substandard or counterfeit products, as these generate higher profit margins than legitimate products[19].

IV. REGULATORY FRAMEWORK AND ENFORCEMENT CAPACITY

Legal Framework

India's primary pharmaceutical regulatory framework comprises:

The Drugs and Cosmetics Act, 1940 and Rules, 1945: This foundational legislation establishes the regulatory authority structure and enforcement mechanisms. Section 17 specifically addresses counterfeit medicines, defining them and establishing penalties for manufacture, sale, and distribution.

Schedule Y (Clinical Trial Requirements): While primarily focused on clinical trial oversight, Schedule Y establishes reporting requirements for pharmacovigilance and adverse events with implications for counterfeit drug detection[20].

Central Drugs Standard Control Organisation (CDSCO): The apex regulatory body under the Ministry of Health and Family Welfare, CDSCO is responsible for setting quality standards, approving new drugs, and coordinating with state-level drug controllers for enforcement.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

State Drugs Controllers: India's federal structure delegates significant regulatory authority to State Drugs Controllers in each state, creating 28+ regulatory jurisdictions with variable enforcement capacity.

The legal framework provides for imprisonment and substantial fines for counterfeit drug-related offenses. In 2003, the Mashelkar Committee recommended introducing capital punishment (death penalty) for manufacture and sale of counterfeit medicines causing grievous harm, though this recommendation has not been implemented[21].

Enforcement Capacity and Workforce Shortages

A critical barrier to effective counterfeit drug regulation in India is the systematic and documented shortage of drug inspectors. Research from Maharashtra—which contains 29% of India's pharmaceutical manufacturing units and 38% of medicines exports—revealed:

- In 2009-2010, 55% of sanctioned drug inspector posts were vacant.
- This represented an 83% shortfall from the Mashelkar Committee's recommended workforce planning norms.
- Less than one-quarter of required inspections of manufacturing and sales units were undertaken.
- Despite subsequent years of attention, inspector shortages persist across most Indian states.

The Indian Drugs and Cosmetics Act and its Rules/Regulations lack specific workforce planning provisions despite the growth and increasing complexity of India's pharmaceutical industry. This structural oversight has prevented systematic workforce expansion responsive to market growth[22].

Penalties and Deterrence

The penalty structure under Indian pharmaceutical law includes:

- Fines up to 1,000,000 Indian Rupees (approximately $12,000 USD).
- Imprisonment up to 10 years for repeat offenders or cases causing serious harm.
- License suspension or permanent cancellation.
- Product seizure and destruction.

Despite these penalties, deterrence effectiveness remains questionable. The high profit margins of counterfeit drug operations (often 300-500%), combined with limited inspection frequency and probability of detection, suggest that rational economic actors may continue engaging in counterfeiting despite potential penalties[23].

V. HEALTH CONSEQUENCES AND CLINICAL IMPACT

Documented Adverse Events

A systematic literature review of health consequences of falsified medicines identified 48 documented incidents across 25 countries involving approximately 7,200 casualties, including 3,604 deaths. The distribution of these incidents was approximately equal between developing (56.3%) and developed countries (43.7%), indicating that counterfeit medicines pose global health risks.

Specific documented health consequences include:

- **Acute Renal Failure:** Multiple well-documented outbreaks have resulted from diethylene glycol (DEG)-contaminated medications, most notably in Panama (2006), China (2008), and other regions. DEG, a toxic chemical used in industrial applications, has been substituted for glycerin or propylene glycol in counterfeit formulations, causing acute renal failure, electrolyte disturbances, and death.
- **Hypoglycemic Emergencies:** Counterfeit antidiabetic medications containing undisclosed hypoglycemic agents (including glibenclamide or other sulfonylureas) have caused severe hypoglycemia requiring emergency hospitalization[24].
- **Toxic Encephalopathy and Neurological Complications:** Counterfeit medications contaminated with neurotoxic compounds have caused encephalopathy, seizures, and permanent neurological damage.
- **Treatment Failures:** Substandard or counterfeit antimicrobials containing subtherapeutic doses result in treatment failures—persistent infections despite apparent medication compliance—leading to disease progression, complications, and death.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

- **Adverse Drug Reactions from Toxic Adulterants:** Medications containing undeclared additives (heavy metals, bacteria, pyrogens, or inappropriate chemical substitutions) cause allergic reactions, organ toxicity, and infection[25].

Antimicrobial Resistance and Population-Level Consequences

Beyond individual patient harms, counterfeit and substandard antimicrobials represent a critical but understudied driver of antimicrobial resistance (AMR) emergence. The mechanism is mechanistically straightforward: when patients receive antibiotics at subtherapeutic concentrations—either because of counterfeit substitution or substandard manufacturing—pathogenic organisms are exposed to selective pressure insufficient to eliminate them but sufficient to select for resistance-conferring mutations. These resistant organisms subsequently proliferate and may transmit resistance genes to other pathogens[26].

The epidemiological magnitude of this mechanism remains poorly quantified, but emerging evidence suggests substantial contribution:

- **India's Antibiotic Consumption Crisis:** India records the world's highest annual antibiotic consumption at 13 billion units, compared to 10 billion in China and 7 billion in the United States. This consumption occurs across multiple sectors—human medicine, veterinary use, and agricultural applications—and within a context of both self-medication and counterfeit drug circulation, amplifying selection pressure for resistance[27].
- **Multi-drug Resistant Tuberculosis:** Approximately 50% of multidrug-resistant TB (MDR-TB) cases worldwide occur in China and India. Poor-quality anti-TB medicines, including both counterfeit and substandard products, are documented contributors to MDR-TB emergence.
- **Antimalarial Resistance:** Artemisinin resistance, first documented on the Thai-Cambodian border, has continued to spread and evolve. Counterfeit artemisinin-based combination therapies contribute to this resistance development through subtherapeutic drug exposure.
- **Childhood Mortality:** An estimated 58,000 children in India died from antibiotic resistance-related causes, with counterfeit and substandard antimicrobials identified as contributing factors[28].

Patient Safety and Pharmacovigilance Implications

The health consequences of counterfeit medicines are compounded by under-reporting and delayed recognition. Many adverse outcomes attributable to counterfeit drugs are misattributed to treatment-resistant disease or individual patient factors, delaying identification of systemic problems. Additionally, the Pharmacovigilance Programme of India (PvPI), while well-intentioned, currently operates at limited capacity with a spontaneous reporting rate of less than 1% compared to a global average of 5%. This gap means that adverse events from counterfeit drugs frequently go unrecognized and unreported[29].

VI. PHARMACOVIGILANCE AND SURVEILLANCE INFRASTRUCTURE

Current Pharmacovigilance Structure in India

India established a formal adverse drug reaction (ADR) monitoring system in 1986 with 12 regional centers. In 1997, India became a member of the WHO Programme for International Drug Monitoring, managed by the Uppsala Monitoring Centre in Sweden. The current structure comprises:

- **National Coordination Centre (NCC):**Functions under the Indian Pharmacopoeia Commission, serving as the central hub for India's Pharmacovigilance Programme.
- **Adverse Drug Reaction Monitoring Centers (AMCs):** Approximately 179 ADR monitoring centers currently report to the NCC, distributed across medical colleges and tertiary care centers. These centers are responsible for collecting adverse event reports, entering them into the VigiFlow system (WHO's ICSR management system), and flagging potential drug safety signals.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

- **Rural Pharmacovigilance:** Extended through collaboration with the Indian Council of Medical Research (ICMR), rural pharmacovigilance initiatives allocate funds to ADR monitoring centers and employ qualified pharmacists to collect drug safety data from community settings and submit reports to nearest AMCs[30].

Capacity Limitations and Reporting Gaps

Despite structural improvements, significant limitations persist:

- **Underreporting:** The spontaneous ADR reporting rate in India remains below 1% compared to the global average of 5%, resulting in systematic under-recognition of adverse events. Barriers to reporting include lack of awareness among healthcare professionals, fear of accountability, and absence of robust reporting mechanisms in many settings.
- **Targeted Surveillance:** Limited capacity exists for targeted surveillance specifically focused on counterfeit drug-related harms. Most pharmacovigilance infrastructure focuses on adverse reactions to authentic, approved medications rather than on harm from counterfeit products.
- **Rural Coverage Gaps:** Despite ICMR initiatives, rural areas—where both counterfeit drug prevalence and undetected adverse events may be highest—remain underrepresented in pharmacovigilance networks.
- **Data Integration Limitations:** Integration between pharmacovigilance systems and enforcement agencies (State Drugs Controllers, customs authorities) remains limited, reducing the actionability of detected signals[31].

Enhanced Surveillance Recommendations

Strengthening pharmacovigilance specifically for counterfeit drug detection requires:

- Mandatory reporting of suspected counterfeit medication encounters.
- Integration of retail pharmacy networks into reporting systems.
- Development of digital tools (mobile reporting, rapid alert systems).
- Targeted surveillance in high-risk regions and therapeutic categories.
- Training for healthcare professionals on recognizing counterfeit medications.
- Confidential, non-punitive reporting culture to encourage participation[32].

VII. DETECTION AND AUTHENTICATION TECHNOLOGIES

Current Detection Methods

Authentication of pharmaceuticals currently relies on multiple overlapping approaches, each with inherent limitations:

Visual Inspection: Pharmacists and consumers may assess packaging quality, font clarity, label printing, tamper-evident features, and holographic elements. This method is subject to human error, increasingly sophisticated counterfeiter techniques, and lacks objective criteria[33].

High-Pressure Liquid Chromatography (HPLC): Laboratory-based chemical analysis remains the gold standard for determining active pharmaceutical ingredient identity, quantity, and purity. However, HPLC requires:

- Specialized equipment (cost: $50,000-$200,000 USD)
- Trained personnel
- Laboratory facilities
- 1-3 hours per analysis

These requirements make HPLC impractical for point-of-use detection in retail pharmacies or field surveillance.

- **Mass Spectrometry:** Provides highly specific identification of compounds but suffers from similar limitations as HPLC regarding cost, expertise requirements, and time[34].
- **Portable Analytical Techniques:** Raman spectroscopy, near-infrared spectroscopy (NIR), and other portable analytical methods have been researched for counterfeit detection, offering potential for rapid, field-deployable analysis. However, implementation remains limited due to:

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

- Initial cost barriers
- Need for extensive reference databases
- Training requirements
- Variable performance across drug types[35].

Supply Chain Technologies

Beyond chemical analysis, emerging technologies address counterfeit detection through supply chain tracking:

Serialization and Track-and-Trace Systems: Assigning unique serial numbers to individual product units enables tracking from manufacture through distribution to point-of-use. The Indian pharmaceutical industry has discussed implementation but faces barriers including:

- Cost of implementation and maintenance
- Need for interoperable systems across manufacturers
- Requirement for infrastructure at retail points
- Data security and privacy considerations[36].

Blockchain-Based Systems: Blockchain technology offers decentralized, tamper-proof records of pharmaceutical product movements through supply chains. Proposed systems would assign unique identifiers ("one thing, one code") enabling transparent tracing from manufacture through final dispensing. While theoretically promising, blockchain implementation in India faces barriers including:

- Lack of standardized protocols across industry.
- Limited interoperability with existing systems.
- Data governance and accountability questions.
- Energy and computational requirements[37].

QR Codes and Holograms: Quick Response (QR) codes linked to manufacturer databases can enable consumers and retailers to verify product authenticity by scanning codes and cross-referencing with manufacturer records. However, sophisticated counterfeiters can replicate QR codes, and this system relies on functional internet connectivity—unavailable in many Indian retail settings.

Radio Frequency Identification (RFID): RFID tags embedded in product packaging or attached to individual units enable automated scanning throughout supply chains. RFID offers advantages including non-line-of-sight reading, rapid processing, and integration with inventory management systems. However, RFID implementation faces cost barriers and requires standardized protocols[38].

Technology Gaps and Priorities

The WHO and global pharmaceutical security experts have identified critical gaps in counterfeit detection technology:

- **Affordable, Scalable Field-Deployable Methods:** No currently available technology simultaneously achieves all three attributes—affordability (cost <$500 USD), capability to analyze diverse pharmaceutical formulations, and practical deployment in resource-limited retail settings[39].
- **Real-Time Integration:** Detection technologies must integrate with enforcement agencies and supply chain partners in real-time, enabling rapid response to detected counterfeits.
- **Standardization:** International standardization of detection protocols, reference materials, and acceptable thresholds would facilitate technology adoption across jurisdictions[40].

VIII. POLICY AND REGULATORY INITIATIVES

Indian Government and Industry Responses

Multiple recent policy initiatives have attempted to address counterfeit drug challenges:

- **National Programme to Combat Counterfeit Medicines (NPCM)**: Government efforts to coordinate pharmacovigilance, enforcement, and public awareness, though systematic documentation of program effectiveness is limited.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

- **CDSCO Enforcement Initiatives:** The Central Drugs Standard Control Organisation has undertaken seizure operations targeting counterfeit drugs, though aggregate statistics on seizures, prosecutions, and conviction rates remain difficult to access in standardized formats.
- **Pharmacopoeia Harmonization:** The Indian Pharmacopoeia Commission has worked toward alignment with international pharmacopeial standards (USP, EP) to establish clear quality reference standards.
- **Intellectual Property Enforcement:** Coordination between pharmaceutical manufacturers and enforcement agencies on trademark and patent protection, though this addresses primarily branded counterfeit products rather than unbranded or generic counterfeits[41].

International Collaboration

India participates in international initiatives including:

- **WHO Collaboration:** Through the National Coordination Centre for the Pharmacovigilance Programme of India, India contributes to the WHO's global pharmacovigilance database and has participated in WHO technical guidance development.
- **INTERPOL Operations:** INTERPOL-coordinated operations including Operation Pangea have targeted counterfeit pharmaceutical manufacturers and distributors in India and neighboring countries.
- **Trade Agreement Provisions:** Trade agreements increasingly include provisions for pharmaceutical regulatory cooperation, though enforcement remains inconsistent[42].

IX. BARRIERS TO EFFECTIVE COUNTERFEIT DRUG CONTROL

Systemic and Structural Barriers

Workforce and Capacity Constraints: The documented shortage of drug inspectors, combined with lack of structured workforce planning provisions in pharmaceutical regulations, creates fundamental capacity limitations. Even with improved technology and policy, insufficient inspectors cannot effectively monitor the thousands of manufacturing and retail units across India[43].

- **Supply Chain Opacity:** Limited transparency regarding API sourcing, manufacturing locations, and distribution pathways enables counterfeiters to operate with reduced detection risk. International agreements and industry standards promoting supply chain transparency have achieved limited penetration in India.
- **Economic Incentives:** The high profit margins of counterfeit drugs (300-500%) and relatively low probability of detection and prosecution create strong economic incentives for continued counterfeiting. As long as profit-risk ratios remain favorable, deterrence through penalties will be limited[44].
- **Regulatory Coordination Gaps:** India's federal structure creates multiple regulatory jurisdictions (state drugs controllers, customs authorities, law enforcement agencies), and limited formal coordination mechanisms exist for information sharing and enforcement action across state boundaries.
- **Consumer Awareness and Demand:** Low consumer awareness of counterfeit drug risks and limited ability to visually distinguish counterfeit from authentic products means that demand-side interventions remain underdeveloped[45].

Technological Barriers

- **Cost and Infrastructure:** Most promising detection technologies exceed cost thresholds for implementation in retail pharmacy settings, particularly in rural areas and informal markets where counterfeit prevalence may be highest.
- **Digital Divide:** Technologies dependent on internet connectivity (QR code verification, blockchain verification systems) are impractical in regions with limited digital infrastructure.
- **Standardization Gaps:** Absence of internationally agreed standards for detection, reference materials, and acceptable contamination thresholds creates implementation challenges and allows inconsistent application[46].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

Regulatory and Legal Barriers

- **Definitional Inconsistencies:** Variation in how counterfeit medicines are defined and classified across states creates legal ambiguity and complicates enforcement.
- **Evidence Thresholds:** Criminal prosecution requires establishing chain of custody, conducting chemical analysis, and meeting legal standards of proof. Limited laboratory capacity and forensic expertise delay investigations.
- **Witness Protection:** Limited witness protection mechanisms for pharmacists and others providing evidence in counterfeit drug investigations may deter reporting[47].

X. RECOMMENDATIONS FOR SYSTEMIC IMPROVEMENT

Regulatory and Enforcement Strengthening

Workforce Planning Reform:

Amend the Drugs and Cosmetics Rules to establish evidence-based workforce planning norms aligned with Mashelkar Committee recommendations Create recruitment and retention mechanisms to address inspector vacancies in all states Establish specialized divisions within state drugs controllers' offices focused specifically on counterfeit drug investigations

Inter-Agency Coordination:

Establish formal coordination mechanisms between state drugs controllers, customs authorities, law enforcement, and the Central Bureau of Investigation for counterfeit drug investigations Create centralized reporting system for counterfeit drug seizures and prosecutions across all states Implement rapid alert systems enabling real-time information sharing across jurisdictions

Penalty and Deterrence Enhancement:

Review and strengthen penalty provisions, ensuring they exceed anticipated profit margins from counterfeiting Increase frequency of prosecution by streamlining legal processes and establishing specialized courts for pharmaceutical crime cases Implement asset forfeiture provisions targeting profits from counterfeit operations[48].

Technology and Innovation

Affordable Detection Technology Development:

Fund research and development of field-deployable, cost-effective detection methods (target: <$500 USD per device)Support portable Raman spectroscopy and near-infrared spectroscopy development programs specifically designed for Indian market conditions Establish reference material libraries and calibration standards for diverse pharmaceutical formulations

Supply Chain Technology Implementation:

Develop phased implementation plan for serialization and track-and-trace systems, beginning with high-risk drug categories (antimicrobials, anti-TB medicines)Establish interoperable digital platforms enabling information sharing across manufacturers, distributors, and retailers Create blockchain pilot programs in specific states to evaluate feasibility and effectiveness[49].

Digital Infrastructure Development:

Support offline-capable authentication systems for retail settings with limited internet connectivity
Integrate mobile-based reporting tools enabling rapid reporting of suspected counterfeit encounters

Pharmacovigilance Enhancement

Expanded Surveillance Network:

Expand ADR monitoring centers from 179 to cover all district-level medical facilities and major pharmacy chains
Establish specific surveillance protocols for counterfeit drug detection, including case definitions and reporting requirements
Develop targeted surveillance in high-risk regions identified through enforcement and market data[50]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

Reporting System Improvement:
Implement confidential, non-punitive reporting mechanisms encouraging pharmacists and consumers to report suspected counterfeit encounters
Develop digital reporting platforms (mobile apps, web-based systems) reducing reporting barriers
Create feedback mechanisms informing reporters of investigation outcomes, reinforcing reporting behavior[51].

Integration with Enforcement:
Establish direct communication protocols between pharmacovigilance centers and enforcement agencies
Create rapid response teams capable of field investigation of suspected counterfeit drug clusters[52].

International Cooperation
Supply Chain Transparency:
Implement requirements for pharmaceutical manufacturers to document API sources and manufacturing locations as prerequisite for market authorization Establish bilateral agreements with China (largest API supplier) regarding manufacturing audits and quality assurance Promote international standards for API manufacturer certification and inspection[53].

Regulatory Harmonization:
Align Indian pharmacopeial standards with international standards (USP, European Pharmacopoeia) enabling reciprocal recognition and reducing parallel regulatory burdenParticipate in WHO initiatives for counterfeit drug detection protocol standardization[54].

Information Sharing:
Establish systematic information sharing with INTERPOL, Europol, and other international law enforcement agencies regarding counterfeit drug manufacturing and distribution networksParticipate in cross-border enforcement operations targeting major counterfeit drug supply chains[55].

Consumer and Healthcare Provider Education
Professional Training:
Incorporate counterfeit drug recognition and reporting into pharmacy education curricula
Develop continuing education programs for practicing pharmacists on authentication methods and reporting procedures
Train healthcare providers to recognize clinical presentations potentially indicating counterfeit drug use[56].

Public Awareness:
Develop multimedia campaigns educating consumers on counterfeit drug risks, authentication methods, and reporting mechanisms
Partner with community health workers to deliver counterfeit drug education in rural areas
Establish hotlines and digital platforms enabling consumer reporting of suspected counterfeits[57].

XI. RESEARCH GAPS AND FUTURE DIRECTIONS

Epidemiological Research
Critical gaps remain in understanding counterfeit drug epidemiology in India:

- **Prevalence studies:** Systematic, geographically representative prevalence surveys using standardized sampling and chemical analysis methods are needed to establish baseline prevalence rates by state, drug category, and distribution channel
- **Source identification:** Research elucidating counterfeit drug manufacturing locations, supply chains, and distribution networks would inform enforcement prioritization

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

- **Consumer behavior studies:** Qualitative and quantitative research examining why consumers purchase from potentially counterfeit sources, what authentication strategies consumers employ, and how counterfeit prevalence affects healthcare-seeking behavior[58].

Health Consequences Research

Adverse event attribution: Research developing methods to identify and attribute adverse events to counterfeit drug exposure, particularly in settings with multiple concurrent morbidity risks

- **Antimicrobial resistance mechanisms:** Quantitative studies examining the specific contribution of counterfeit and substandard antimicrobials to observed resistance patterns in India.
- **Population-level burden:** Systematic estimation of mortality and morbidity attributable to counterfeit drugs using epidemiological methods analogous to those employed in disease burden studies[59].

Technology Development

- **Detection technology validation:** Comparative studies validating novel detection methods against established reference standards across diverse pharmaceutical formulations
- **Implementation science:** Research evaluating feasibility, effectiveness, and sustainability of serialization, blockchain, and other supply chain technologies in Indian market conditions
- **Standardization research:** Studies developing and validating internationally agreed standards for detection protocols, reference materials, and contamination thresholds[60].

Regulatory and Policy Research

- **Enforcement effectiveness:** Evaluative research assessing impact of enforcement interventions (inspections, seizures, prosecutions) on market prevalence of counterfeit drugs
- **Incentive structures:** Research examining wholesaler, retailer, and manufacturer economic incentives and how regulatory or market-based interventions might alter these incentives to reduce counterfeiting
- **Workforce optimization:** Research informing optimal staffing models, training requirements, and specialization patterns for pharmaceutical regulatory workforce[61].

XII. CONCLUSION

The proliferation of counterfeit, substandard, and falsified medicines in the Indian pharmaceutical market represents a complex public health challenge requiring multifactorial intervention spanning regulatory strengthening, technology innovation, supply chain reform, healthcare system integration, and international cooperation. While India has established foundational regulatory structures and participated in global initiatives addressing pharmaceutical counterfeiting, critical implementation gaps persist. The documented shortage of pharmaceutical inspectors, opacity in supply chains particularly at the active pharmaceutical ingredient level, limited detection capacity in retail settings, and underdeveloped pharmacovigilance infrastructure for counterfeit-specific surveillance collectively create conditions enabling continued market circulation of counterfeit medicines.

The health consequences are substantive and measurable: documented cases of acute renal failure, severe hypoglycemia, toxic encephalopathy, and treatment failures span India's geography and affect both pediatric and adult populations. Beyond individual harm, counterfeit antimicrobials represent a neglected but significant driver of antimicrobial resistance emergence, contributing to an estimated 58,000 antibiotic-related deaths annually in India. The disproportionate targeting of essential medicines for infectious diseases—antibiotics, antimalarials, anti-TB medications—threatens decades of progress in communicable disease control programs and undermines public confidence in the healthcare system.

Evidence-based solutions exist but require systematic implementation. Workforce planning reforms addressing documented inspector shortages, technology innovations enabling affordable field-deployable detection methods, enhanced pharmacovigilance infrastructure specifically focused on counterfeit drug identification, supply chain

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 6, Issue 4, January 2026 Impact Factor: 7.67

transparency initiatives particularly at the API level, and international cooperation mechanisms targeting cross-border counterfeit drug operations all represent feasible interventions with demonstrated effectiveness in other contexts.

The urgency of addressing this challenge is underscored by both immediate patient safety concerns and longer-term threats to therapeutic effectiveness and antimicrobial stewardship. Success will require sustained commitment from pharmaceutical regulatory authorities, law enforcement agencies, healthcare professionals, industry stakeholders, and international partners, coupled with adequate resource allocation and integration across traditionally siloed sectors. The Indian pharmaceutical industry's global leadership in generic drug manufacturing positions the nation to serve as a model for counterfeit drug prevention in low- and middle-income countries, but only with decisive action to strengthen regulatory systems, innovate detection technologies, and eliminate the structural vulnerabilities currently enabling counterfeit medicines to circulate through Indian markets.

REFERENCES

[1]. Indian pharmaceutical companies, cited in news reports; "Counterfeit drugs form 10% of world's drug trade" WHO sources
[2]. Industry estimates on counterfeit prevalence in major Indian cities
[3]. Combating Counterfeit and Substandard Medicines in India: Legal Framework and the Way Ahead
[4]. The good, the bad and the ugly!! - Antibiotics; India antibiotic mortality data
[5]. Why India Failed to Penalize those Responsible for the Circulation of Substandard Medicines and Vaccines while China Succeeded
[6]. Faking it - I The Menace of Counterfeit Drugs
[7]. WHO definition of counterfeit medicines
[8]. Current Scenario of Spurious and Substandard Medicines in India: A Systematic Review
[9]. Substandard and counterfeit medicines: a systematic review of the literature
[10]. International Diabetes Federation and ICMR data on diabetes prevalence in India
[11]. WHO definition and classification framework for counterfeit medicines
[12]. Counterfeit medicines sale on online pharmacies in India
[13]. Responding to the Pandemic of Falsified Medicines
[14]. Combating Counterfeit and Substandard Medicines in India: Legal Framework and the Way Ahead (detailed definitions)
[15]. Sub-standard or Sub-legal? Distribution, Pharma Dossiers, and Fake-talk in India
[16]. Faking it - I The Menace of Counterfeit Drugs (WHO 10% estimate)
[17]. Current Scenario of Spurious and Substandard Medicines in India: A Systematic Review
[18]. Combating Counterfeit and Substandard Medicines in India: Legal Framework and the Way Ahead ($200 billion valuation, 67% dangerous)
[19]. The health consequences of falsified medicines- A study of the published literature (56.3% developing countries)
[20]. India pharmaceutical industry global position and export volumes
[21]. Why India Failed to Penalize those Responsible for the Circulation of Substandard Medicines and Vaccines while China Succeeded
[22]. Substandard and counterfeit medicines: a systematic review of the literature (prevalence ranges)
[23]. Substandard and counterfeit medicines: a systematic review of the literature (28.5% median prevalence)
[24]. Substandard/Counterfeit Antimicrobial Drugs (beta-lactams, fluoroquinolones)
[25]. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines
[26]. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines (artemisinin derivatives)
[27]. Probing newer possibilities for detecting drug resistance in malaria (artemisinin resistance India risk)

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, January 2026
Impact Factor: 7.67

[28]. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines (drug-resistant TB)
[29]. Supply chain transparency and the availability of essential medicines (India procures 70% APIs from China)
[30]. Insights from a qualitative study of the procurement and manufacture of active pharmaceutical ingredients in India
[31]. Insights from a qualitative study of the procurement and manufacture of active pharmaceutical ingredients in India (supply chain transparency gaps)
[32]. Supply chain transparency and the availability of essential medicines (transparency gaps at API level)
[33]. Assessment of Counterfeit Medicines and Supply Chain Integrity in Pakistan's Pharmaceutical Market (informal outlets 35% failure rate)
[34]. Counterfeit medicines sale on online pharmacies in India
[35]. Vigilance for Sale of Drugs through Online Pharmacies
[36]. ONLINE PHARMACIES: AN EMERGING TREND IN INDIAN HEALTHCARE SCENARIOS
[37]. Marketing and Distribution System Foster Misuse of Antibiotics in the Community: Insights from Drugs Wholesalers in India
[38]. The case of the 'Spurious Drugs Kingpin': shifting pills in Chennai, India
[39]. The case of the 'Spurious Drugs Kingpin': shifting pills in Chennai, India (relabeling and recirculation mechanism)
[40]. Marketing and Distribution System Foster Misuse of Antibiotics in the Community: Insights from Drugs Wholesalers in India (wholesaler incentive structures)
[41]. Combating Counterfeit and Substandard Medicines in India: Legal Framework and the Way Ahead (Drugs and Cosmetics Act, Section 17)
[42]. Current Scenario of Spurious and Substandard Medicines in India: A Systematic Review (legal framework)
[43]. Regulatory developments in the conduct of clinical trials in India (Schedule Y)
[44]. Correcting India's Chronic Shortage of Drug Inspectors (state drug controllers, federal structure)
[45]. India to introduce death penalty for peddling fake drugs (Mashelkar Committee recommendation)
[46]. Correcting India's Chronic Shortage of Drug Inspectors (Maharashtra workforce data, 55% vacancies, 83% shortfall)
[47]. Correcting India's Chronic Shortage of Drug Inspectors (persistent inspector shortages across states)
[48]. Faking it - II: Countering and preventing counterfeiting of drugs (penalties and deterrence)
[49]. Global pharmaceutical supply chain vulnerabilities (profit margins, detection probability)
[50]. The health consequences of falsified medicines- A study of the published literature (7200 casualties, 3604 deaths, 48 incidents)
[51]. The health consequences of falsified medicines- A study of the published literature (diethylene glycol outbreaks)
[52]. The health consequences of falsified medicines- A study of the published literature (hypoglycemic emergencies)
[53]. Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
[54]. Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines (AMR mechanisms)
[55]. The good, the bad and the ugly!! - Antibiotics (India antibiotic consumption, MDR-TB, childhood mortality)
[56]. Effects of the Global Pharmaceutical Drug Trade on Multi-drug Resistance Tuberculosis (MDR-TB) in India
[57]. A Prospective Observational Study Of Monitoring And Reporting Of Antimicrobial Drugs Associated Adverse Drug Reactions (pharmacovigilance rate <1%)
[58]. System of adverse drug reactions reporting: What, where, how, and whom to report? (PvPI history)
[59]. Pharmacovigilance Programme of India: Recent developments and future perspectives (179 AMCs)
[60]. Drug safety alerts of pharmacovigilance programme of India (VigiFlow system)
[61]. Another feather in the crown of medical safety and ethics in India (rural pharmacovigilance)